Synopsys (SNPS) CRO Awarded Restricted Stock Units
SYNOPSYS INC
Subscribe to track SNPS
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Synopsys (SNPS) CRO Awarded Restricted Stock Units
Company: SYNOPSYS INC (SNPS) Form: 4 | Filed: 2025-12-18 Significance: Low
Insider: Ellow Michael Title: Chief Revenue Officer | Relationship: Officer
Transaction: • Type: Grant • Shares: 6,475 Restricted Stock Units • Price: $0.00 • Value: $0 • Owned After (Derivatives): 30,761 units
Key Insight: This is a routine equity grant to an executive as part of a compensation plan. The number of shares is negligible, representing less than 0.004% of total shares outstanding, indicating minimal dilution.
This is PUBLIC SEC data for educational purposes. Not investment advice.
Comprehensive Analysis
SEC Filing Analysis: SYNOPSYS INC (SNPS)
Executive Summary
- Trading Significance: Low
- Key Takeaway: Michael Ellow, Chief Revenue Officer of Synopsys, was awarded 6,475 Restricted Stock Units (RSUs) as part of a standard executive compensation package.
- Market Impact: The transaction has a neutral market impact due to its nature as a pre-planned equity grant with zero cost and negligible dilutive effect.
Company Information
| Field | Value |
|---|---|
| Company | SYNOPSYS INC |
| Ticker Symbol | SNPS |
| CIK | 0000883241 |
| Industry | SERVICES-PREPACKAGED SOFTWARE |
Insider Information
| Field | Value |
|---|---|
| Name | Ellow Michael |
| CIK | 0001615442 |
| Title/Position | Chief Revenue Officer |
| Relationship | Officer |
Transaction Details
| Field | Value |
|---|---|
| Form Type | 4 |
| Transaction Date | 2025-12-16 |
| Transaction Code | A (Grant) |
| Security Type | Restricted Stock Units |
| Shares Involved | 6,475 |
| Price Per Share | $0.00 |
| Total Value | $0 |
| Shares Owned After | 30,761 (Derivative securities) |
| Ownership Type | Direct |
Financial Impact Assessment
Transaction Materiality
| Metric | Value |
|---|---|
| Transaction Value | $0 |
| % of Market Cap | 0.0% |
| Shares Transacted | 6,475 |
| % of Shares Outstanding | 0.0035% |
| Post-Transaction Ownership | 30,761 RSUs (potential for ~0.017% of outstanding) |
| Materiality Assessment | Low |
Impact Evaluation
- Market Cap Context: Synopsys is a large-cap company with a market capitalization of $72.41 billion. This grant, valued at $0 upon issuance, is immaterial in this context.
- Ownership Concentration: The insider's total holdings, including these new RSUs, remain a very small fraction of the company's total shares outstanding.
- Dilution Impact: The 6,475 shares underlying the RSUs represent approximately 0.0035% of the total shares outstanding. This is a negligible dilutive event for existing shareholders and is a routine part of employee compensation for a company of this size.
- Transaction Significance: The transaction is classified as low significance. It is not an open-market purchase or sale, but a standard compensation grant, which carries little to no predictive power for future stock performance.
Market Impact Analysis
Stock Impact Prediction
- Direction: Neutral
- Reasoning: Equity grants are a common form of executive compensation and are not typically interpreted as a bullish or bearish signal by the market. The size of the grant is immaterial relative to the company's market capitalization and shares outstanding.
Volume & Sentiment
- Expected Volume Impact: None. This is not an open-market transaction and will not directly impact trading volume.
- Sentiment Indicator: Neutral. The filing is a routine disclosure of executive compensation.
Additional Context
Transaction Notes
- Vesting Schedule: The RSUs are subject to a vesting schedule. According to the filing's footnote, one-sixth of the units will vest on June 15, 2026, followed by five equal semi-annual installments, contingent on continued service.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.
